We also observed that combining the USP8 inhibitor with anti-PD-1 or anti-PD-L1 therapy significantly retarded the CT26 tumor growth and dramatically improved the overall survival compared with either treatment alone (Fig. 6c, d and Supplementary Fig. 6d). The gene discussed is USP8; the disease is neoplasm.